Bcl-2、COX-2在宫颈癌新辅助化疗前后的表达及临床意义的研究

doi:10.3969/j.issn.1000-8535.2016.06.002

广州医药 ›› 2016, Vol. 47 ›› Issue (6): 6-9.DOI: 10.3969/j.issn.1000-8535.2016.06.002

Bcl-2、COX-2在宫颈癌新辅助化疗前后的表达及临床意义的研究

林悦欢¹, 胡璐萍², 何慧仪², 伍华玲²

1 中山大学附属江门医院妇产科(江门 529100)
2 广州医科大学附属广州市第一人民医院妇产科(广州 510180)

收稿日期:2016-09-21 出版日期:2016-11-20 发布日期:2021-12-02
通讯作者: 何慧仪, E-mail:winniehhy2010@qq.com
基金资助:
广东省科技计划项目(2012B031800328)

A study of the expression and clinical significance of the Bcl-2 and COX-2 in cervical cancer before and after neoadjuvant chemotherapy

Lin Yuehuan, Hu Luping, He Huiyi, Wu Hualing

Lin Yuehuan. Department of Obstetrics and Gynecology,Jiangmen Hospital Affiliated to Sun Yat-sen University,Jiangmen 529100, China
Hu Luping,He Huiyi,Wu Hualing.Department of Obstetrics and Gynecology, First People's Hospital of Guangzhou Affiliated to Guangzhou Medical University,Guangzhou 510180, China

Received:2016-09-21 Online:2016-11-20 Published:2021-12-02

摘要/Abstract

摘要： 目的探讨Bcl-2、COX-2在宫颈癌新辅助化疗前后表达的意义, 以及新辅助化疗(NACT)对宫颈癌的近期临床疗效。方法对32例宫颈癌患者,采集NACT治疗前后的宫颈癌组织标本,采用免疫组织化学SP法检测组织中的Bcl-2及COX-2表达。结果 ①经NACT后,治疗总有效率(CR+PR)为75%,无效率(PD+SD)为25%。②宫颈癌组织中Bcl-2、COX-2的表达均出现明显下降,差异均有统计学意义(P<0.05);临床有效组中Bcl-2、COX-2的表达在NACT后出现显著下降(P<0.05),无效组中Bcl-2、COX-2的表达在NACT前后无明显统计学意义(P>0.05)。结论 Bcl-2、COX-2的表达情况对评价宫颈癌患者新辅助化疗效具有肯定的临床意义,宫颈癌行NACT后近期疗效良好。

关键词: 宫颈癌, Bcl-2, COX-2, 新辅助化疗

Abstract: Objective To investigate the expression of Bcl-2 and COX-2 in cervical cancer before and after neoadjuvant chemotherapy; To evaluate the efficacy of neoadjuvant chemotherapy(NACT) for cervical cancer in the recent clinical effects. Methods To select 32 cases of patients with cervical cancer, collect the cervical cancer tissues before and after NACT, immunohistochemical SP method was used to detect the expression of Bcl-2and COX-2 in the tissues. Results After neoadjuvant chemotherapy, total effective rate (CR+PR) was 75%(24/32), inefficient rate(PD+SD) was 25%(8/32). The expression of Bcl-2 and COX-2 of cervical cancer patients who had neoadjuvant chemotherapy (NACT), before and after, had great differences. The difference had statistical significance (P<0.05); The expression of Bcl-2 and COX-2 were significantly lower after neoadjuvant chemotherapy in clinical effective group(P<0.05), there is no statistical significance in clinical non-effective group(P>0.05). Conclusion The expression of Bcl-2 and COX-2 of cervical cancer patients has certain clinical significance in evaluating the effect of neoadjuvant chemotherapy in cervical cancer patients. Recent curative effect after NACT in the cervical cancer patients is good.

Key words: Cervical cancer, B-cell lymphoma/leukemia-2(Bcl-2), Cyclooxygenase-2(COX-2), Neoadjuvant chemotherapy(NACT)

林悦欢, 胡璐萍, 何慧仪, 伍华玲. Bcl-2、COX-2在宫颈癌新辅助化疗前后的表达及临床意义的研究[J]. 广州医药, 2016, 47(6): 6-9.

Lin Yuehuan, Hu Luping, He Huiyi, Wu Hualing. A study of the expression and clinical significance of the Bcl-2 and COX-2 in cervical cancer before and after neoadjuvant chemotherapy[J]. Guangzhou Medical Journal, 2016, 47(6): 6-9.

参考文献

[1] 谢幸,苟文丽.妇产科学(第8版)[M]. 北京:人民卫生出版社,2013.304.
[2] 杨炜敏,袁力,何善阳,等.KAI1 转移抑制基因在宫颈鳞癌中的表达及临床意义[J]. 广州医药,2009,40(4):25-27.
[3] LEI T, MAO WM, LEI TH, et al. Incidence and mortality trend of cervical cancer in 11 cancer registries of China[J]. Chin J Cancer Res, 2011, 23(1):10-14.
[4] 林仲秋,王丽娟.国际妇产科联盟2012宫颈癌诊治指南解读[S]. 中国实用妇科与产科杂志,2013,29(5):323-325.
[5] 林悦欢,何慧仪.检测Bcl-2、COX-2在宫颈病变诊断中的可行性研究[J]. 中国妇幼保健,2013,28(28):4618-4620.
[6] ZHOU XL, WANG M. Expression levels of survivin, Bcl-2, and KAI1 proteins in cervical cancer and their correlation with metastasis[J]. Genet Mol Res, 2015,14(4):17059-17067.
[7] 朱华,施铮铮. Survivin、Bcl-2、HPV 16/18 在宫颈上皮内瘤变及宫颈癌中的表达及临床意义[J]. 实用妇产科杂志,2010,26(1):57-60.
[8] PROTRKA Z, ARSENIJEVIC S, et al. Co-overexpression of bcl-2 and c-myc in uterine cervix carcinomas and premalignant lesions[J]. Eur J Histochem, 2011,55(1):44-49.
[9] 刘美兰,李乐云.COX-2和mPGEs-1与肿瘤关系的研究进展[J]. 中华肿瘤防治杂志,2010,17(14):1134-1137.
[10] 陆俊国,杨磊,谭清和,等.非小细胞肺癌组织COX-2和HER-2表达及其临床意义[J]. 中华肿瘤防治杂志,2010,17(3):206-212.
[11] DEMPKE W, RIE C, et al. Cyclooxygenase-2: a novel target for cancer chemotherapy[J]. Cancer Res Oncol,2001,127(7):411-417.
[12] 张琦,许进琼.环氧合酶-2及核因子-κB在宫颈癌组织中的表达及意义[J]. 现代医药卫生,2009,25(6):2417-2418.
[13] SCHMITT CA, ROSENTHAL CT, LOWE SW. Genetic analysis of chemoresistance in primary murine lymphomas[J]. Nat Med, 2000,6(9):1029-1035.
[14] SZOSTAK M, KAUR P, AMIN P, et al. Apoptosis and bcl-2 expression inprostate cancer significance in clinical outcome after brachytherapy[J]. J Urol, 2001,165(6 Pt 1):2126-2130.
[15] 黄艳,金淑静,柳红,等. P-gp和Bcl-2在大肠癌中的表达及相关性的研究[J]. 广州医药,2004,35(2):6-9.
[16] NAGAI G, KANELLETTI FO, LEGGE F, et al. Cyelooxygenase-2(COX-2) expression in locally advanced cervical cancer patients undergoing chemoradiation plus surgery. Int J Radiat Oncol Biol Phys, 2003,55(l):21-27.
[17] FERRANDINA G, RANELLETTI FO, LEGGE F, et al. Prognostic role of the ratio between cyclooxygenase-2 in tumor and stroma compartmentsin cervical cancer[J]. Clin Cancer Res, 2004,10(9):3117-3123.

Bcl-2、COX-2在宫颈癌新辅助化疗前后的表达及临床意义的研究

A study of the expression and clinical significance of the Bcl-2 and COX-2 in cervical cancer before and after neoadjuvant chemotherapy

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 10

编辑推荐

Metrics

本文评价

[1]	徐双, 周锋, 范娜. 超声引导下宫颈癌根治术的应用效果及对患者远期生存率的影响[J]. 广州医药, 2021, 52(5): 64-68.
[2]	朱清红, 陈小君, 甘庆权. 千伏锥形束CT(kV-CBCT)图像引导宫颈癌放射治疗的三维摆位误差分析[J]. 广州医药, 2021, 52(5): 113-116.
[3]	蔡蘅, 江少如. 腹腔镜下早期宫颈癌根治术与开腹手术的临床疗效评价[J]. 广州医药, 2021, 52(2): 127-130.
[4]	敖泽飞, 唐际存, 王梨明, 甘华杨, 余贵斌. 新辅助化疗联合保肢手术治疗四肢骨肉瘤的临床研究[J]. 广州医药, 2018, 49(6): 75-78.
[5]	吴俐俐, 杨文丰. 妇科门诊宫颈癌高危人群采取阴道镜检查后配合宫颈细胞学检查对宫颈癌筛查临床价值[J]. 广州医药, 2017, 48(5): 78-80.
[6]	张月桃, 陈中文, 王斌, 胥琳璟. 鳞癌抗原表达对宫颈癌手术治疗后临床转归的预测价值[J]. 广州医药, 2017, 48(4): 104-106.
[7]	江淑意, 刘微华, 梁惠玲. 追踪护理模式对中青年保留神经宫颈癌根治术后膀胱功能的影响[J]. 广州医药, 2017, 48(3): 86-88.
[8]	李明尧, 朱土福, 张春宁. 注射用黄芪多糖对宫颈癌化疗患者骨髓抑制的效果分析[J]. 广州医药, 2016, 47(5): 36-38.
[9]	陈能, 唐蔚. 南沙区宫颈癌HPV筛查认知研究[J]. 广州医药, 2016, 47(2): 95-95.
[10]	邱海江, 袁穗蓉, 张柳. 氧化苦参碱对视网膜母细胞瘤细胞凋亡的诱导作用及机制[J]. 广州医药, 2015, 46(1): 52-54.